drugset / Trial / NCT02846545

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

NCT02846545

Phase 2 Completed 84 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).

Timeline

Start
2016-08-26
Primary completion
2019-05-21
Completion
2021-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody Subcutaneous